Mid
A
AMGNAI Stock Diagnostic Report
Amgen, Astra post late-stage trial win for asthma drug Tezspire in swallowing disorder
Amgen and AstraZeneca's asthma treatment Tezspire succeeded in a Phase 3 trial for an esophageal inflammatory disease.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time